Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.40% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-03-31 was 1.40%, a 12.50% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2015-03-31 was 1.60%, a 5.88% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2014-03-31 was 1.70%, a 100.00% increase year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2013-03-31 was 0.85%, a 4.49% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.40%, a 17.65% decline from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 1.70%, a 5.56% decline from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2014 was 1.80%, a 2.86% increase from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.75%, a 96.63% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | 1.40% 10-K · filed 2017-02-24 | ||||
| 2016-09-30 | 1.40% 10-Q · filed 2016-11-04 | ||||
| 2016-06-30 | 1.40% 10-Q · filed 2016-08-05 | ||||
| 2016-03-31 | 1.40% 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | 1.70% 10-K · filed 2017-02-24 | ||||
| 2015-09-30 | 1.70% 10-Q · filed 2016-11-04 | ||||
| 2015-06-30 | 1.70% 10-Q · filed 2016-08-05 | ||||
| 2015-03-31 | 1.60% 10-Q · filed 2016-05-06 | ||||
| 2014-12-31 | 1.80% 10-K · filed 2017-02-24 | 1.75% 10-K · filed 2015-03-16 | |||
| 2014-09-30 | 1.75% 10-Q · filed 2015-11-02 | ||||
| 2014-06-30 | 1.70% 10-Q · filed 2015-08-07 | ||||
| 2014-03-31 | 1.70% 10-Q · filed 2015-05-08 | ||||
| 2013-12-31 | 1.75% 10-K · filed 2016-03-14 | ||||
| 2013-09-30 | 1.39% 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | 1.13% 10-Q · filed 2014-08-13 | ||||
| 2013-03-31 | 0.85% 10-Q · filed 2014-05-14 | ||||
| 2012-12-31 | 0.89% 10-K · filed 2014-03-21 | ||||
| 2012-09-30 | 0.89% 10-Q · filed 2013-11-13 | ||||
| 2012-06-30 | 0.89% 10-Q · filed 2013-08-12 | ||||
| 2012-03-31 | 0.89% 10-Q · filed 2013-05-09 | ||||
| 2011-09-30 | 2.29% 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | 2.29% 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |